1. Home
  2. MEIP vs ARBB Comparison

MEIP vs ARBB Comparison

Compare MEIP & ARBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • ARBB
  • Stock Information
  • Founded
  • MEIP 2000
  • ARBB 1997
  • Country
  • MEIP United States
  • ARBB Singapore
  • Employees
  • MEIP N/A
  • ARBB N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • ARBB EDP Services
  • Sector
  • MEIP Health Care
  • ARBB Technology
  • Exchange
  • MEIP Nasdaq
  • ARBB Nasdaq
  • Market Cap
  • MEIP 13.3M
  • ARBB 11.9M
  • IPO Year
  • MEIP 2003
  • ARBB 2023
  • Fundamental
  • Price
  • MEIP $2.53
  • ARBB $6.84
  • Analyst Decision
  • MEIP Hold
  • ARBB Strong Buy
  • Analyst Count
  • MEIP 1
  • ARBB 1
  • Target Price
  • MEIP N/A
  • ARBB $20.00
  • AVG Volume (30 Days)
  • MEIP 21.5K
  • ARBB 14.8K
  • Earning Date
  • MEIP 05-13-2025
  • ARBB 07-11-2025
  • Dividend Yield
  • MEIP N/A
  • ARBB N/A
  • EPS Growth
  • MEIP N/A
  • ARBB N/A
  • EPS
  • MEIP N/A
  • ARBB N/A
  • Revenue
  • MEIP N/A
  • ARBB $24,425,491.00
  • Revenue This Year
  • MEIP N/A
  • ARBB N/A
  • Revenue Next Year
  • MEIP N/A
  • ARBB N/A
  • P/E Ratio
  • MEIP N/A
  • ARBB N/A
  • Revenue Growth
  • MEIP 33.76
  • ARBB N/A
  • 52 Week Low
  • MEIP $1.46
  • ARBB $3.22
  • 52 Week High
  • MEIP $4.10
  • ARBB $18.60
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 78.43
  • ARBB 44.21
  • Support Level
  • MEIP $2.21
  • ARBB $6.49
  • Resistance Level
  • MEIP $2.95
  • ARBB $7.46
  • Average True Range (ATR)
  • MEIP 0.15
  • ARBB 0.59
  • MACD
  • MEIP 0.05
  • ARBB 0.16
  • Stochastic Oscillator
  • MEIP 81.48
  • ARBB 72.66

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About ARBB ARB IOT Group Limited

ARB IOT Group Ltd is engaged in provision of hardware and software of Internet of Things Solutions to meet customers' demand in four business lines, which are IoT Smart Home and Buildings, IoT Smart Agriculture, IoT System Development, and IoT Gadget Distribution. The company delivers holistic solutions with full turnkey deployment from designing, installation, testing, pre-commissioning, and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company has two operating segments: Internet of Things ('IoT'), Investment holding and others. It earns its maximum profit from the Internet of Things (IoT) segment.

Share on Social Networks: